All News

7 December 2010

Apexigen, Inc. Announces Collaboration for Antibody DiscoveryAntibodies

7 December 2010

Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory ALCL at ASH Annual MeetingAntibodies

7 December 2010

Halozyme Announces Roche Completes Patient Enrollment in Phase 3 Clinical Trial with Subcutaneous HerceptinAntibodies

6 December 2010

Immunomedics Reports Progress With Milatuzumab at 52nd ASH Annual MeetingAntibodies

6 December 2010

First Results From Phase II Study of Fractionated Radioimmunotherapy With Y-90 Epratuzumab in Aggressive Lymphoma Presented at Hematology ConferenceAntibodies

6 December 2010

Results From Phase II Trial of Epratuzumab and Rituximab as Initial Treatment for Follicular Lymphoma Reported in an Oral Presentation at ASHAntibodies

6 December 2010

New Phase II data from investigational compound GA101 presented today at the American Society of HematologyAntibodies

6 December 2010

Single Dose ZEVALIN in First-Ever Phase 2 Monotherapy Trial for Non-Hodgkin’s Lymphoma Shows Significant and Durable Clinical ResponsesAntibodies

6 December 2010

ImmunoGen, Inc. Announces Presentation of Positive Initial Clinical Data for IMGN901 Used in a Combination Regimen for Multiple MyelomaAntibodies

6 December 2010

Phase III Study Showed Rituxan for Initial Use Followed by Continued Use Delayed the Need for Additional Therapy in People with Asymptomatic Follicular Lymphoma, a Common Type of Blood CancerAntibodies

6 December 2010

Alexion Reports Results from First Clinical Trial of Novel Anti-Cancer Antibody Samalizumab at ASH Annual MeetingAntibodies

6 December 2010

Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology MeetingAntibodies

6 December 2010

Long-Term Follow-Up Data from Phase 2 Study Show Micromet’s Blinatumomab Produces Durable Remissions in Patients with Acute Lymphoblastic LeukemiaAntibodies

6 December 2010

Micromet’s Blinatumomab Produces High Objective Response Rate in Spectrum of Relapsed Non-Hodgkin’s Lymphoma PatientsAntibodies

6 December 2010

Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual MeetingAntibodies

6 December 2010

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Subcutaneous Formulation of ORENCIA (abatacept) for Adult Patients with Moderate to Severe Rheumatoid ArthritisAntibodies

6 December 2010

HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FDA EXTENSION OF BENLYSTA PDUFA TARGET DATE TO MARCH 10, 2011Antibodies

2 December 2010

MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic LeukemiaAntibodies

1 December 2010

Peregrine Announces Initiation of Phase I/II Investigator-Sponsored Trial in Liver CancerAntibodies

1 December 2010

Tolerx and the Cancer Research Institute Enter Collaboration to Accelerate Development of TRX518, a First-in-Class Anti-GITR Antibody for Cancer TreatmentAntibodies

30 November 2010

ImmunoGen, Inc. Announces Initiation of Randomized Clinical Trial Evaluating IMGN901 for First-Line Treatment of Small-Cell Lung CancerAntibodies

29 November 2010

Thallion and LFB Initiate Phase II SHIGATEC TrialAntibodies

24 November 2010

Innate Pharma Initiation of a Phase II Clinical Trial with Anti-KIR Monoclonal Antibody IPH 2101 in Smoldering Myeloma PatientsAntibodies

22 November 2010

Phase 2 Study of Eculizumab (Soliris®) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical SignificanceAntibodies

22 November 2010

Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular DegenerationAntibodies

22 November 2010

f-star and Boehringer Ingelheim to Collaborate in Discovery and Development of Therapeutic AntibodiesAntibodies

19 November 2010

FDA Approves Amgen’s XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid TumorsAntibodies

19 November 2010

ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Data for IMGN388 at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsAntibodies

18 November 2010

Stromedix Expands its Fibrosis Pipeline Through In-Licensing Agreement with UCSFAntibodies

18 November 2010

Curis Presents CUDC-101 Phase I Clinical Data and CU-201 Preclinical Data at 22nd EORTC-NCI-AACR SymposiumAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD73 Inhibitor Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Nectin-4-Targeted Immunotherapy Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

PSMA-Targeted Therapy Pipeline Review